# Phase Approval Records

Approval evidence per Master Prompt §23. Decisions: `APPROVED`, `APPROVED_WITH_CONDITIONS`,
`REJECTED`, `BLOCKED`. Approvers are **role-based authorities**, not fictional individuals.
A conditional approval is never treated as unconditional release approval.

---

## APR-P0-001

| Field | Value |
|---|---|
| Phase | P0 — Repository Reconnaissance |
| Phase version | 1.0 |
| Approver role | Master Orchestrator |
| Supporting review | System Architect / Engineering |
| Date/time | 2026-09-07 (UTC) |
| Decision | **APPROVED** |
| Acceptance criteria reviewed | "Team understands what already exists before modifying it" |
| Evidence reviewed | Full filesystem enumeration (3 files); complete read of `DESIGN.md`; git history (1 commit); toolchain probe; secret scan of all files |
| Outstanding issues | R0-2 (HIGH, design-system conflict) and R0-3 (MEDIUM, fonts) — both deferred to P8 with a defined resolution path; neither affects P1 |
| Risk assessment | Acceptable. Greenfield baseline means no legacy constraints and no risk of overwriting prior work. |
| Conditions | None |
| Linked artefacts | `docs/P0-repository-reconnaissance.md`, `DESIGN.md` |
| Linked tests | N/A (no code exists) |
| Linked requirements | Seeds REQ-091 (design compliance), REQ-097 (accessibility) |
| Linked findings | R0-1, R0-2, R0-3; risks R-01…R-06 |
| Comments | Reconnaissance is complete and honest about the emptiness of the repository. The one substantive artefact, `DESIGN.md`, was read in full and reduced to binding constraints rather than skimmed. |

---

## APR-P1-001

| Field | Value |
|---|---|
| Phase | P1 — Problem Definition |
| Phase version | 1.0 |
| Approver role | Product Manager |
| Supporting review | Pharmaceutical Supply-Chain Domain Expert |
| Date/time | 2026-09-07 (UTC) |
| Decision | **APPROVED_WITH_CONDITIONS** |
| Acceptance criteria reviewed | "Problem can be explained in one precise paragraph" — satisfied (§1) |
| Evidence reviewed | Problem statement; 5 personas with distinct decision authorities; primary journey and counter-journey; failure modes F-1…F-8; KPIs K-1…K-8; scope and non-goals; flagship scenario rationale |
| Outstanding issues | Pharmaceutical/regulatory claims remain uncited |
| Risk assessment | R-01 (scope) mitigated by the single-flagship-scenario decision. Residual risk that the scenario is still too large is passed to P2 to constrain. |
| **Conditions** | **(C1)** No uncited pharmaceutical, clinical or regulatory claim may appear in the UI, README or deck; such claims must be cited by P16 or removed. **(C2)** The three Domain-Expert challenges (cold-chain feasibility as a gate, per-market supplier qualification, shelf-life netting) are binding on P4/P5 and are not negotiable down to "soft cost terms". |
| Linked artefacts | `docs/P1-problem-definition.md` |
| Linked tests | N/A at this phase |
| Linked requirements | REQ-012, REQ-022, REQ-023, REQ-103, REQ-104 (from C2); REQ-085 (from C1) |
| Linked findings | Domain-Expert challenges 1–3 (§13) |
| Comments | The Domain Expert's challenges materially changed the design rather than being recorded and ignored; that is the intended function of the adversarial review. The counter-journey (rejected recommendation) being made a first-class requirement is what distinguishes this from a demo script. |

---

## APR-P2-001

| Field | Value |
|---|---|
| Phase | P2 — Architecture |
| Phase version | 1.0 |
| Approver role | System Architect (primary) |
| Supporting review | AI Architect, SAP Strategy Specialist, Master Orchestrator; plus Product Manager, Domain Expert, Data Architect, Competition Analyst evaluations |
| Date/time | 2026-09-07 (UTC) |
| Decision | **APPROVED_WITH_CONDITIONS** |
| Acceptance criteria reviewed | "Architecture is technically, commercially, SAP and agentically defensible" |
| Evidence reviewed | Three genuinely distinct architectures differing in locus of control; 13-criterion weighted matrix (A=148, B=200, C=240/275); mapping of every P1 failure mode to an architectural mechanism; SAP capability verification with public-source citations; six independent role evaluations with recorded dissent |
| Outstanding issues | AR-R1 (agents may appear decorative), AR-R2, AR-R3, AR-R4 |
| Risk assessment | Principal residual risk is AR-R1 — the honest weakness identified by the Competition Analyst. Mitigated by condition CA-2 but not eliminated until P6 demonstrates that scenario intents change generated output. |
| **Conditions** | PM-1 (P8), DE-1 (P5), DE-2 (P5), AI-1 (P6), AI-2 (P11), DA-1 (P4), DA-2 (P4), SAP-1 (P7), SAP-2 (P18), CA-2 (P6). Each is assigned an owning phase; no owning phase may pass while its condition is open. |
| Linked artefacts | `docs/architecture.md`, `docs/P2-architecture-review.md`, ADR-0001…ADR-0004 |
| Linked tests | Deferred: REQ-062/063 (P11), REQ-083 (P10), REQ-072 (P7) |
| Linked requirements | All 74 in `docs/SRS.md`; architectural rules AR-1…AR-7 mapped in `traceability.md` §3 |
| Linked findings | AR-R1…AR-R4; CA-1 |
| Comments | Architecture C was selected unanimously but not uncritically. The decision that seam S4 (policy evaluation) has **no agent** is the load-bearing choice: it is what makes governance structural rather than prompt-dependent. The Competition Analyst's CA-1 concern ("your agents are just fancy summarisers") is recorded as a fair criticism rather than dismissed, and condition CA-2 exists specifically to make it untrue. |

---

## APR-P3-001

| Field | Value |
|---|---|
| Phase | P3 — Requirements |
| Phase version | 0.1.0 |
| Approver role | Requirements Manager |
| Supporting review | Product Manager, System Architect |
| Date/time | 2026-09-07 (UTC) |
| Decision | **APPROVED** |
| Acceptance criteria reviewed | "Every major requirement maps to design and future verification" |
| Evidence reviewed | `SRS.md` (62 functional + 12 non-functional requirements, each with priority, owning phase and verification method); `traceability.md` showing 74/74 requirements traced to a design artefact, 7/7 architectural rules covered, 10/10 P2 conditions covered, 8/8 failure modes covered, zero orphans |
| Outstanding issues | Implementation/Test/Evidence columns are 0% populated |
| Risk assessment | Low. The empty downstream columns are correct at baseline; the risk is only that they are not maintained, which the P4+ Definition of Done addresses. |
| Conditions | None. (Note: the P2 conditions remain open against their own owning phases; they are not P3's to close.) |
| Linked artefacts | `docs/SRS.md`, `docs/traceability.md` |
| Linked tests | None yet — by design |
| Linked requirements | REQ-001…REQ-105, NFR-001…NFR-012 |
| Linked findings | None new |
| Comments | Approved specifically because the traceability matrix demonstrates *coverage of the conditions and failure modes*, not merely a list of requirements. NFR-010 (every requirement appears in the matrix) is self-verifying and is the only requirement currently marked VERIFIED — correctly so. |

---

## Pending
No approval records exist for P4–P21. P4 is unblocked and is the next phase.
